Mallinckrodt Plc (MNK) has announced it will spin off its speciality generics business to shareholders in 2019. The company previously announced its intention to divest the generics business and has been reporting it as discontinued operations. The separation will be completed through a pro-rata distribution of common stock to shareholders.
The full update is available here on the FIIG website available to wholesale investors only.